Medical Mutual coverage for Wegovy (Heart Disease

Employer / Commercial Insurance

Depends on your plan's benefit

Prior Authorization is only available for members with plan benefit coverage of weight loss drugs. Medications for the treatment of weight loss are specifically excluded as a covered benefit for many plans.

What you need to qualify

Age 18 and older
BMI of 27 or higher
6 months of a documented diet and exercise program
Established cardiovascular disease (MI, stroke, and PAD)
On guideline-directed medical therapy (optimized pharmacotherapy for established cardiovascular disease)

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction in Established CVD with Obesity/Overweight

All of:

Patient is >= 18 years of age
Patient has a BMI >= 27 kg/m2
According to the prescriber, the medication will be used in combination with optimized pharmacotherapy for established cardiovascular disease
Medication will be used concomitantly with a behavioral modification program and a reduced-calorie diet

Plus any one of:

Patient has had a prior myocardial infarction
Patient has had a prior stroke (not including TIA)
Patient has a history of symptomatic peripheral arterial disease evidenced by: intermittent claudication with ankle-brachial index < 0.85, OR peripheral arterial revascularization procedure, OR amputation due to atherosclerotic disease

Documentation to bring

Documentation of BMI >= 27 kg/m2
Documentation of qualifying cardiovascular event: prior MI, prior stroke (not TIA), or symptomatic PAD (with ankle-brachial index < 0.85, revascularization, or amputation due to atherosclerotic disease)
Prescriber attestation that medication will be used in combination with optimized pharmacotherapy for established cardiovascular disease

Approval and renewal

Initial approval: 6 months

Not covered when

Transient ischemic attack (TIA) does not qualify as a prior stroke
Concomitant use with other FDA-approved weight loss medications
Concomitant use with other GLP-1 agonists or GLP-1/GIP agonists

Policy note: Approval is for 6 months initial duration. No explicit continuation criteria listed for CV risk reduction indication. Wegovy oral or injectable forms are both applicable. The policy does not explicitly state that diabetes is excluded for this indication — no excludes_diabetes flag applied.

verified June 10, 2026 · source: Weight-Loss-GlucagonLike-Peptide1-GLP1-Agonists.pdf

Medical Mutual coverage for Wegovy (Heart Disease Risk Reduction)